Healthy individuals who utilize the Helix consumer platform will be able to select health applications from Invitae pending approval by a clinician. Invitae will then provide a full interpretation of the results, with a focus on actionable findings related to cancer and cardiovascular disease.

The Helix apps will complement Invitae’s existing menu of high-quality genetic testing, which will continue to be based in Invitae’s own College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory.

Invitae’s health-related scans on the Helix platform are expected to be available in 2017.